Friday, July 10, 2026

pharma · Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) · Advanced Solid Tumor

Daiichi Sankyo US

Daiichi Sankyo US is a pharma organization headquartered in basking ridge, USA. Primary therapeutic focus areas include Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor, No medical conditio

211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US HQ
4,386 Employees
NMPA registrant Type
Company details
Status
Public
HQ
211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US
Employees
4,386
Programs
58
Drugs
66
Patents
0
Clinical program

First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors

Phase 1 · other · Advanced Solid Tumors

First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors for Advanced Solid Tumors is a Phase 1 program (other) at Daiichi Sankyo with 1 ClinicalTrials.gov record(s).

Internal code DS3610-071

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Daiichi Sankyo
Phase
Phase 1
Modality
other
Indication
Advanced Solid Tumors
Status
active
Trials
1

Clinical trials